Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors

Gene Therapy

Volumn 6, Issue 2, 1999, Pages 227-236

  Praus, M ^a   Wauterickx, K ^a   Collen, D ^a   Gerard, R D ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Adenovirus; Gene transfer; Metastasis; Plasminogen activator

Indexed keywords

LUCIFERASE; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METASTASIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; EXPRESSION VECTOR; FIBRINOLYSIS; GENE INSERTION; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER CELL; LUNG METASTASIS; METASTASIS; MOUSE; PRIORITY JOURNAL; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL; TUMOR CELL CULTURE; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANALYSIS OF VARIANCE; ANIMALS; CELL MOVEMENT; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; LIVER; MICE; MICE, NUDE; NEOPLASM METASTASIS; PLASMINOGEN INACTIVATORS; STATISTICS, NONPARAMETRIC; TUMOR CELLS, CULTURED;

EID: 0032993493     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300802     Document Type: Article

References (42)

1. Thorgeirsson UP, Lindsay CK, Cottam DW, Gomez DE. Tumor invasion, proteolysis and angiogenesis. J Neuro-Oncol 1994; 18: 89-103.
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
3. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.
4. Blasi F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. BioEssays 1993; 15: 105-110.
5. Simpson AJ, Booth NA, Moore NR, Bennett B. Distribution of plasminogen activator inhibitor (PAI-1) in tissue. J Clin Pathol 1991; 44: 139-143.
6. Fearns C, Loskutoff DJ. Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol 1997; 150: 579-590.
7. Wiman B, Almquist A, Sigurdardottir O, Lindahl T. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma. FEBS Lett 1988; 19: 125-128.
8. 3 binding to vitronectin. Nature 1996; 383: 441-443.
9. Kjoller L et al. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420-429.
10. Waltz DA et al. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100: 58-67.
11. Jensen PH et al. Urokinase binds to a plasminogen activator inhibitor type-2-like molecule in placental microvillous membranes. Biochim Biophys Acta 1989; 986: 135-140.
12. von Hijne G et al. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem 1991; 266: 15240-15243.
13. Kumar S, Baglioni C. Protection from tumor necrosis mediated cytolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-20964.
14. Mikus P, Urano T, Liljestrom P, Ny T. Plasminogen-activator inhibitor type 2 (PAI-2) is a spontaneously polymerising SERPIN. Biochemical characterisation of the recombinant intracellular and extracellular forms. Eur J Biochem 1993; 218: 1071-1082.
15. Stahl A, Mueller BM. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 1994; 54: 3066-3071.
16. Kook YH, Adamski J, Zelent A, Ossowski L. The effect of anti-sense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 1994; 13: 3983-3991.
17. Alizadeh H et al. Tissue-type plasminogen activator induced invasion and metastasis of murine melanomas. Curr Eye Res 1995; 14: 449-458.
18. Soff GA et al. Expression of plasminogen activator inhibitor type 1 in human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in athymic mouse model. J Clin Invest 1996; 96: 2593-2600.
19. Mueller BM, Yu YB, Laug WE. Overexpression of plasminogen activator inhibitor 2 in human melanoma cells inhibits spontaneous metastasis in scid/scid mice. Proc Natl Acad Sci USA 1995; 92: 205-209.
20. Astedt B, Billstrom A, Lecander I. Urokinase-producing tumour growth in SCID mice inhibited by recombinant PAI-2. Fibrinolysis 1995; 9: 175-177.
21. Laug WE et al. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res 1993; 53: 6051-6057.
22. Ma D et al. Inhibition of metastasis of intraocular melanomas by adenoviral gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997; 90: 2738-2746
23. Carmeliet P et al. Inhibitory role of pharminogen activator inhibitor-1 in arterial wound healing and neointima formation. A gene targeting and gene transfer study in mice. Circ 1997; 96: 3180-3190.
24. Rasheed A et al. Characterization of a newly derived human sarcoma cell line (HT-1080). Cancer 1974; 33: 1027-1033.
25. Laug WE et al. Clonal variation of expression of the genes coding for plasminogen activators, their inhibitors and the urokinase receptor in HT-1080 sarcoma cells. Int J Cancer 1992; 52: 298-304.
26. Eitzman DT et al. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87: 4718-4722.
27. Carmeliet P et al. Urokinase-generated plasmin is a candidate activator of metalloproteinases during atherosclerotic aneurism formation. Nature 1997; 17: 439-444.
28. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993; 194: 1234-1241.
29. Bikfalvi A et al. Interaction of vasculotropin/vascular endothelial growth factor with human umbilical vein endothelial cells: binding, internalization, degradation and biochemical effects. J Cell Physiol 1991; 149: 50-59.
30. Jankun J, Selman S, Swiercz R, Skrzypczak-Jankun E. Why drinking green tea could prevent cancer. Nature 1997; 387: 561.
31. Declerk P, van Keer L, Verstrecken M, Collen D. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA. Thromb Haemostas 1992; 67: 95-100.
32. Holvoet P, Cleemput H, Collen D. Assay of tissue-type plasminogen activator with enzyme-linked immunosorbent assay (ELISA) based on three murine monoclonal antibodies to t-PA. Thromb Haemostas 1985; 54: 684-687.
33. Declerk P et al. Measurement of PAI-1 in biological fluids with murine monoclonal antibody-based enzyme linked immunoassay. Blood 1988; 8: 220-225.
34. Fallaux FJ et al. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 1996; 7: 215-222.
35. Gerard RD, Meidell RS. Adenovirus vectors. In: Hames BD, Glover D (eds) DNA Cloning - A Practical Approach: Mammalian Systems. Oxford University Press: Oxford, 1995, pp 285-307.
36. Bett AJ, Krougliak V, Graham FL. DNA sequence of the deletion/insertion in early region 3 of Ad5dl309. Virus Res 1995;39: 75-82.
37. 4isomerase from placenta: expression in nonsteroidogenic cells of a protein that catalyzes the dehydrogenation/isomerization of C21 and C19 steroids. Endocrinology 1990; 126: 2493-2498.
38. Antalis TM et al. Cloning and expression of a cDNA coding for a human monocyte-derived plasminogen activator inhibitor. Proc Natl Acad Sci USA 1988; 85: 985-989.
39. Shubeita HE, Cottey TL, Franke AE, Gerard RD. Mutational and immunochemical analysis of plasminogen activator inhibitor 1. J Biol Chem 1990; 265: 18379-18385.
40. Herz J, Gerard RD. Adenovirus-mediated transfer of low density lipoprotein receptor acutely accerates cholesterol clearance in normal mice. Proc Natl Acad Sci USA 1993; 90: 2812-2816.
41. van Doren K, Hanahan D, Gluzman Y. Infection of eucaryotic cells by helper-independent recombinant adenoviruses: early region I is not obligatory for integration of viral DNA. J Virol 1994; 50: 606-614.
42. Dowell RT, Gairola CG, Diana JN. Reproductive organ blood flow measured using radioactive microspheres in diestrous and estrous mice. Reg Integ Comp Physiol 1992;31: R666-R670.